A New Approach to Treating a Rare Endocrine Disorder

David Katz, founder and chief scientific officer of Sparrow Pharmaceuticals, discusses the company’s efforts to develop approach to treating Cushing’s syndrome, how it works, and why this has the potential to address the unmet needs of patients with endogenous Cushing’s syndrome.